Ultragenyx (RARE) delivered earnings and revenue surprises of -12.10% and 1.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.24 per share. The biotechnology company posted revenue of $164.9 million in the period, which topped ...

Antennas receive and transmit electromagnetic waves, delivering information to our radios, televisions, cellphones and more.

Management outlined significant revenue contributions from TRYNGOLZA and donidalorsen in 2025. TRYNGOLZA is positioned to increase patient identification and diagnosis over time, with a gradual launch ...

Nissan and Honda ended merger talks to forge a $60 billion car company on Thursday, pitching Nissan deeper into uncertainty ...

Consequently, food companies are rushing to reformulate products for protein lovers. That’s a category that includes both people taking the powerful new class of obesity drugs known as GLP-1s, who are ...

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

INNOVATE Corp. surged 150% after its subsidiary MediBeacon received FDA approval for its TGFR system. See why I rate VATE ...